Observations placeholder
Lucentis and Ranibizumab
Identifier
017611
Type of Spiritual Experience
Background
A description of the experience
Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.
Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting Vascular endothelial growth factor A, a mechanism similar to Bevacizumab.
It is often used for age-related wet macular degeneration. Its effectiveness is similar to that of bevacizumab.
On Jan, 10, 2017 15,593 people reported to have side effects when taking Lucentis.
Among them, 22 people (0.14%) have Hallucination
Time on Lucentis when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On Aug, 14, 2015: 9,569 people reported to have side effects when taking Lucentis. Among them, 1,983 people (20.72%) have Death.
Time on Lucentis when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 13.86% | 27.71% | 16.27% | 24.10% | 16.87% | 1.20% | 0.00% |
Gender of people who have Death when taking Lucentis :
Female | Male | |
Death | 57.68% | 42.32% |
Age of people who have Death when taking Lucentis :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Death | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.74% | 0.89% | 98.37% |
Top conditions involved for these people :
- Age-related macular degeneration (259 people, 13.06%)
- Macular degeneration (174 people, 8.77%)
- Diabetic retinopathy (30 people, 1.51%)
- Choroidal neovascularisation (26 people, 1.31%)
- Retinal vein occlusion (26 people, 1.31%)